Lead sponsor
Second Xiangya Hospital of Central South University
4 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
4
Trials led
0
Active
190
Total enrollment
4
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 1/2
1
Phase 4
2
Trials by status
Unknown
4
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.BMI 24-35Ph 4Unknown120
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes—Ph 1/2Unknown40